Autonomix Medical (AMIX) Q1 2025 earnings summary

Executive summary

• Pre-revenue, clinical-stage medical device company focused on nervous system disorders; no revenues for the three months ended June 30, 2024 or 2023.

• Net loss of $2.7 million for the quarter ended June 30, 2024, up from $0.9 million in the prior year period.

• Cash and cash equivalents of $6.8 million and working capital of $6.3 million as of June 30, 2024.

• Current cash resources expected to fund operations into, but not beyond, Q2 2025; additional capital required to continue operations.

Financial highlights

• Operating expenses increased to $2.8 million for the quarter, up 216% year-over-year, driven by higher G&A and R&D costs.

• General and administrative expenses rose to $1.8 million (up $1.3 million), mainly due to increased compensation, stock-based compensation, legal, and insurance costs.

• Research and development expenses increased to $1.0 million, primarily due to clinical trial planning and development.

• Net cash used in operating activities was $1.9 million for the quarter.

• No revenue recognized; accumulated deficit reached $41.7 million as of June 30, 2024.

Outlook and guidance

• Company expects to incur increased R&D costs as clinical trials progress.

• Additional financing of approximately $40 million estimated to be required to fund operations through the clinical phase.

• Substantial doubt exists about the ability to continue as a going concern without new capital.